NGNE

Neurogene Inc. (NGNE) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Neurogene Inc. is a clinical-stage biotechnology company focused on developing gene therapies for complex neurological diseases using its proprietary EXACT^TM transgene regulation technology. The company's lead program, NGN-401, is in a Phase 1/2 clinical trial for Rett syndrome. The company operates as a single segment and is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Revenue was $0 for the three and six months ended June 30, 2025, compared to $0.9 million in the same periods of 2024. The prior year revenue consisted of upfront licensing payments from legacy Neoleukin assets.
• Net Loss: Net loss increased to $22.0 million (Q2) and $44.7 million (YTD) in 2025, compared to $18.5 million and $35.4 million in 2024, respectively.
• Operating Expenses: Total operating expenses rose to $26.1 million (Q2) and $52.0 million (YTD) in 2025, up from $21.1 million and $39.8 million in 2024.
  • R&D: Increased to $19.4 million (Q2) and $37.1 million (YTD), driven by higher clinical trial costs for the NGN-401 Rett syndrome program and increased manufacturing costs.
  • G&A: Increased to $6.7 million (Q2) and $14.9 million (YTD), primarily due to higher stock-based compensation and personnel costs.
• Liquidity: Cash and cash equivalents decreased from $136.6 million at year-end 2024 to $58.8 million at June 30, 2025. However, short-term investments increased to $215.7 million, resulting in total liquid assets of approximately $274.5 million.

Outlook, Risks, and Management Commentary

• Clinical Progress: Dosing in the Phase 1/2 trial for NGN-401 (Rett syndrome) is complete with 10 participants dosed at the 1E15 vg level. The company has received FDA alignment on the design for the "Embolden" registrational trial. A high-dose cohort (3E15 vg) was discontinued in late 2024 following a participant death due to a rare hyperinflammatory syndrome; no such events have occurred at the 1E15 vg dose.
• Program Status: The company does not expect to move forward with the NGN-101 program for CLN5 Batten disease following the denial of RMAT designation by the FDA in November 2024.
• Liquidity: Management expects current cash and investments ($274.5 million) to fund operations for at least 12 months beyond the filing date. The company anticipates substantial increases in expenses as it advances clinical trials.
• Recent Financing: In August 2025, the company entered into an At-The-Market (ATM) sales agreement with Leerink Partners to sell up to $150.0 million of common stock.
• Regulatory & Tax: The company is evaluating the impact of the "One Big Beautiful Bill" (OBBB) Act signed in July 2025, which restores immediate expensing of domestic R&D expenses.
• Risks: Key risks include the failure of clinical trials, inability to secure additional capital, manufacturing challenges, and the potential for adverse events in gene therapy trials. The company also faces contingent value rights (CVR) liabilities related to legacy lease and tax obligations from the reverse merger.

Investor Verification Checklist

• Verify the timeline and enrollment status of the "Embolden" registrational trial for NGN-401.
• Confirm the specific financial impact of the discontinued NGN-101 Batten disease program and any remaining wind-down costs.
• Monitor the utilization of the new $150 million ATM facility and its potential dilution impact.
• Review the company's cash burn rate relative to the $274.5 million liquidity position to validate the "12-month runway" assertion.
• Assess the status of Contingent Value Rights (CVR) liabilities, specifically the upcoming payment due in August 2025.